Zydus Lifesciences: Forms New U.S. Subsidiary, Zara Merger Sub Inc.

Smartworks: Outlook - Fy27 And Beyond - Co Enters Fy27 With A Strong Multi-year Contracted Rental Revenue Visibility Of More Than Rs 5,200 Cr.

KFIN Tech: Focuses On Cost Savings And Aims To Attract Fund Managers With Over USD 100M In Assets To Boost Efficiency.

Greenply Industries:' Management Declares Double-Digit Margins in Plywood Segment as New Standard - Concalls Update

Greenply Industries: Expects 25-30% Growth in MDF Volume by 2027, According to Concall Update

Adani Power: Considers Global Projects In Thermal And Hydro Sectors To Broaden Its Reach Beyond India - Concall Update

Bharat Coking Coal: Revisional Authority Directed State Authorities Of Jharkhand Not To Take Coercive Action Against Co

Bharat Forge: To Discuss Q4 Results And Dividend On May 7

Bajaj Auto: Board To Consider Buyback Of Equity Shares In Meeting On 6 May 2026

Hindustan Unilever: Company Expects Group EBITDA Margin To Stay Within Current Guidance

Hindustan Unilever: Expects FY'27 Performance To Improve Compared To FY'26 Due To Portfolio And Channel Changes, Amid Increased Geopolitical Tensions Causing Commodity And Currency Fluctuations.

Hindustan Unilever: Expects FY27 To Outperform FY26 Thanks To Portfolio Improvements.

Waaree: Co CMD Predicts FY 27 Will Outperform FY 26 || Co. Expects 20% Growth In EBITDA To Continue.- CNBC

Indegene: EBITDA Margins Are Set to Return to Higher Levels in H2 FY 2027, Backed by a Robust Pipeline of Outcome-Based Contracts and the Biopharm Acquisition Integration - Concall Update

Biocon: U.S. FDA Finishes Pre-License Review At Biocon's Bengaluru Biosimilars Plant; Notes 5 Procedural Observations But No Data Issues Found.

SUN PHARMA ADVANCED RESEARCH COMPANY: U.S. FDA Approves PRV for Sun Pharma's Seizaby, Treating Neonatal Seizures

Bajaj Finance: Expects Small Decrease In NIM, Ongoing OPEX To Result In 25 To 40 Basis Points Improvement In NTI, And A Drop In Credit Costs (145 To 160 BPS). Profitability Goals For FY'27 Include ROA Of 4.4% To 4.6% And ROE Of 19% To 20%, While GNPA And NNPA Stay Stable.